Scoop has an Ethical Paywall
Geneious present at Antibody Engineering conference
Jannick Bendtsen, PhD, will address how next generation sequencing (NGS) is accelerating the field of therapeutic antibody research at the Antibody Engineering & Therapeutics conference, at the Manchester Grand Hyatt in San Diego, on December 11.
Dr Bendtsen’s talk - titled NGS is Accelerating Therapeutic Antibody Discovery: What Lies Beyond? - will examine how scientists face a growing need for software that enables efficient and accurate analysis of rapidly expanding data sets. He will also outline how Biomatters’ Geneious Biologics cloud-based enterprise software for analysis of antibodies and related constructs meets that need.
Dr Bendtsen is Vice President of Technology Services at Biomatters and development leader of Geneious Biologics. He will be joined in his presentation by Dr Liuhong Chen, Ph.D., Discovery Biology Team Lead at Bicycle Therapeutics.
Scientific Briefing: NGS is Accelerating
Therapeutic Antibody Discovery: What Lies
Beyond?
Presenter: Jannick Bendtsen, PhD, Vice President of
Technology Services, Biomatters
Event: Antibody
Engineering & Therapeutics
Location: Manchester Grand
Hyatt, San Diego
Date: 11 December 2018
Time: 12:00
PM (PT), Bayview Room
John Mazenier: Gaffer Tape And Glue Delivering New Zealand’s Mission Critical Services
Earthquake Commission: Ivan Skinner Award Winner Inspired By Real-life Earthquake Experience
Reserve Bank: Consultation Opens On A Digital Currency For New Zealand
NIWA: Ship Anchors May Cause Extensive And Long-lasting Damage To The Seafloor, According To New Research
New Zealand Customs Service: A Step Forward For Simpler Trade Between New Zealand And Singapore
Horizon Research: 68% Say Make Banks Offer Fraud Protection
